Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
Nicolas Jacquelot, Cyril Seillet, Minyu Wang, Angela Pizzolla, Yang Liao, Soroor Hediyeh-zadeh, Sharon Grisaru‐Tal, Cynthia Louis, Qiutong Huang, Jaring Schreuder, Fernando Souza-Fonseca-Guimarães, Carolyn A. de Graaf, Kevin Thia, Sean Macdonald, Mary Camilleri, Kylie Luong, Shengbo Zhang, Michaël Chopin, Tristan Molden-Hauer, Stephen L. Nutt, Viktor Umansky, Bogoljub Ćirić, Joanna R. Groom, Paul S. Foster, Philip M. Hansbro, Andrew N. J. McKenzie, Daniel H.D. Gray, Andreas Behren, Jonathan Cebon, Éric Vivier, Ian P. Wicks, Joseph A. Trapani, Ariel Munitz, Melissa J. Davis, Wei Shi, Paul J. Neeson, Gabrielle T. Belz
Topics & Concepts
Innate lymphoid cellMelanomaCytokineImmune systemImmunologyCancer researchBiologyImmunotherapyInnate immune systemBlockadeTumor microenvironmentCancer immunotherapyReceptorBiochemistryIL-33, ST2, and ILC PathwaysImmune Cell Function and InteractionEosinophilic Esophagitis